SRR1500800
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1394297 | GTEX | — | 0.968 |
| 2 | SRR1358561 | GTEX | — | 0.964 |
| 3 | SRR1361795 | GTEX | — | 0.961 |
| 4 | SRR1414424 | GTEX | — | 0.955 |
| 5 | SRR1467294 | GTEX | — | 0.955 |
| 6 | SRR1331289 | GTEX | — | 0.951 |
| 7 | BS_2SHWPB5P | ganglioneuroblastoma | — | 0.951 |
| 8 | SRR1323536 | GTEX | — | 0.951 |
| 9 | BS_HHPA8NJ2 | Med | Medulloblastoma | 0.949 |
| 10 | SRR1489971 | GTEX | — | 0.948 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INFLAMMATORY_RESPONSE | 0.514 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.499 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.385 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.382 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.381 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.372 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.368 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.356 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.349 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.329 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.297 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.267 | Inavolisib | — uncovered |
| COAGULATION | 0.261 | Binimetinib | — uncovered |
| MYOGENESIS | 0.238 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.237 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.177 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.177 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.154 | Inavolisib | — uncovered |
| HYPOXIA | 0.117 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.107 | Cobimetinib | — uncovered |